Abstract
The most crucial variable that affects a drug's bioavailability is its aqueous solubility. One of the most significant issues facing the pharmaceutical business is improving water solubility, which is the key to improving therapeutic efficacy. During the first screening procedure, over 50% of recently created medications are discovered to be insoluble or weakly soluble. The solubility of the medicine can be increased using various techniques. The method entails both chemical and physical drug modifications. Any medicine that is absorbed must be present at the absorption site as a solution. Poorly soluble medications can be made more soluble using a variety of approaches, like physical and chemical alterations to the drug and other strategies. Using a surfactant, complexation, and so on are examples of solid dispersion. Pharmacological properties, absorption sites, and the requirements for the dosage form influence the choice of a solubility-improving technology. In order to serve as a quick reference, this study attempted to gather information on various solubility improvement methods and organize it systematically.
[http://dx.doi.org/10.22270/jddt.v9i2.2437]
[http://dx.doi.org/10.13005/bpj/1920]
[http://dx.doi.org/10.3923/tasr.2012.596.619]
[http://dx.doi.org/10.1016/j.ejpb.2004.03.001] [PMID: 15296954]
[http://dx.doi.org/10.1002/jps.20869] [PMID: 17323349]
[http://dx.doi.org/10.1021/acs.chemmater.8b02212] [PMID: 30197469]
[http://dx.doi.org/10.3923/ajdd.2011.160.173]
[http://dx.doi.org/10.2174/1570180819666220822115049 ]
[http://dx.doi.org/10.1016/j.ejmech.2005.08.002] [PMID: 16226353]
[http://dx.doi.org/10.1002/jps.2600550610] [PMID: 5924122]
[http://dx.doi.org/10.1016/j.addr.2007.05.011] [PMID: 17597252]
[http://dx.doi.org/10.1016/j.ijpharm.2006.01.008] [PMID: 16469459]
[http://dx.doi.org/10.1208/s12249-022-02386-7]
[http://dx.doi.org/10.1155/2015/216375]
[http://dx.doi.org/10.3390/pr8060709]
[http://dx.doi.org/10.1016/0378-5173(91)90047-R]
[http://dx.doi.org/10.1002/jps.2600560712] [PMID: 6034828]
[http://dx.doi.org/10.7897/2230-8407.0811210]
[http://dx.doi.org/10.3923/jms.2001.193.199]
[http://dx.doi.org/10.1016/j.reprotox.2013.07.023] [PMID: 23954440]
[http://dx.doi.org/10.1002/anie.199523111]
[http://dx.doi.org/10.1248/cpb.53.634] [PMID: 15930773]
[http://dx.doi.org/10.1016/j.powtec.2010.10.009]
[http://dx.doi.org/10.3923/ajdd.2011.144.159]
[http://dx.doi.org/10.1002/14651858.CD010678.pub3]
[http://dx.doi.org/10.1208/s12249-008-9176-z] [PMID: 19115110]
[http://dx.doi.org/10.1016/S0731-7085(03)00576-4] [PMID: 15127807]
[http://dx.doi.org/10.4103/2230-973X.167689] [PMID: 26682195]
[http://dx.doi.org/10.1211/jpp.57.12.0003] [PMID: 16354397]
[PMID: 24381597]
[http://dx.doi.org/10.1007/s13311-017-0552-9] [PMID: 28653280]
[http://dx.doi.org/10.4103/2230-973X.195931] [PMID: 28123991]
[http://dx.doi.org/10.1016/j.ejps.2016.01.029] [PMID: 26836368]
[http://dx.doi.org/10.1080/10717540802035301] [PMID: 18712620]
[http://dx.doi.org/10.22270/jddt.v11i2.4756]
[http://dx.doi.org/10.1208/s12249-021-01995-y] [PMID: 33835317]
[http://dx.doi.org/10.4103/2230-973X.76726] [PMID: 23071917]
[http://dx.doi.org/10.1016/j.xphs.2020.10.010] [PMID: 33049259]
[http://dx.doi.org/10.2174/2210303110999201007164919]
[http://dx.doi.org/10.5402/2011/819765] [PMID: 22389861]
[http://dx.doi.org/10.1016/j.ijpharm.2005.05.017] [PMID: 16024189]
[http://dx.doi.org/10.1080/03639040902783074] [PMID: 19640249]
[PMID: 25657806]
[http://dx.doi.org/10.4103/0973-8398.56306]
[http://dx.doi.org/10.1182/bloodadvances.2022007793] [PMID: 35816636]
[http://dx.doi.org/10.1248/cpb.c15-00838] [PMID: 27039831]
[http://dx.doi.org/10.1016/S0378-5173(99)00191-X] [PMID: 10502627]
[http://dx.doi.org/10.3390/solids2010003]
[http://dx.doi.org/10.1016/j.molstruc.2018.02.060]
[http://dx.doi.org/10.1016/S0091-6749(99)70008-4] [PMID: 10588996]
[http://dx.doi.org/10.1016/j.jpba.2004.06.016] [PMID: 15862677]
[http://dx.doi.org/10.1002/jps.2600831011] [PMID: 7884662]
[http://dx.doi.org/10.1002/ddr.21156] [PMID: 24648149]
[http://dx.doi.org/10.3390/pharmaceutics11020056] [PMID: 30704026]
[http://dx.doi.org/10.3390/pharmaceutics14102043] [PMID: 36297478]
[http://dx.doi.org/10.3390/pharmaceutics14010023] [PMID: 35056919]
[http://dx.doi.org/10.1016/j.addr.2016.04.022] [PMID: 27137109]
[http://dx.doi.org/10.1590/s2175-97902022e191024]
[http://dx.doi.org/10.4103/jrptps.JRPTPS_129_19]
[PMID: 32103956]
[PMID: 34567155]
[http://dx.doi.org/10.1016/j.jsps.2019.03.002] [PMID: 31297015]
[http://dx.doi.org/10.37285/ijpsn.2009.2.2.5]
[http://dx.doi.org/10.1111/j.1527-3458.2001.tb00188.x] [PMID: 11420570]
[http://dx.doi.org/10.1093/ofid/ofx232] [PMID: 29255730]
[http://dx.doi.org/10.1016/S1773-2247(12)50096-1]
[http://dx.doi.org/10.1002/j.1875-9114.1981.tb03548.x] [PMID: 6985448]
[PMID: 35432803]
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c00645] [PMID: 33890794]